Cardiac Marker Market
Cardiac Marker Market Size, Share & Trends Analysis Report by Type (Creatine Kinase, Troponins, Myoglobin, Natriuretic Peptides (BNP and NT-proBNP), Ischemia Modified Albumin, and Others), by Application (Acute Coronary Syndrome, Congestive Heart Failure, Cardiac Injury Monitoring, Myocardial Infarction, and Others), and By Testing (Laboratory Testing, and Point of Care Testing) Forecast Period, (2026-2035)
Industry Overview
Cardiac marker market was valued at $4.8 billion in 2025 and is projected to reach $18.0 billion by 2035, growing at a CAGR of 14.3% during the forecast period (2026-2035). The global cardiac marker market is growing due to the rising incidence of acute coronary syndrome and congestive heart failure, which continues to increase diagnostic testing demand across emergency and routine care settings. Greater clinical reliance on biomarkers such as troponins, creatine kinase, and myoglobin for early and accurate cardiac injury detection is strengthening adoption across laboratories and point-of-care environments. Advancements in assay sensitivity and testing technologies are improving diagnostic confidence, supporting wider clinical use in both hospital and outpatient settings. Expanding access to point-of-care testing is further accelerating uptake, particularly in time-critical cardiac assessment scenarios.
Market Dynamics
Increasing Adoption of High-Sensitivity Cardiac Biomarker Assays
The growing adoption of high-sensitivity cardiac biomarker assays is a key trend shaping the global cardiac marker market. These assays enable earlier and more precise detection of myocardial injury, particularly in acute coronary syndrome cases where rapid clinical decisions are critical. Laboratories are increasingly shifting toward high-sensitivity troponin testing to improve diagnostic accuracy and reduce turnaround time. This transition is supporting standardized testing protocols across healthcare systems and strengthening the demand for advanced laboratory-based cardiac marker solutions. As clinical guidelines continue to emphasize early diagnosis, adoption of high-sensitivity assays is expected to remain a sustained growth driver.
Expansion of Point of Care Testing in Emergency and Acute Care Settings
The expanding use of point-of-care testing is emerging as a significant trend in the global cardiac marker market, driven by the need for rapid diagnosis in emergency and critical care environments. Point-of-care cardiac marker tests allow clinicians to assess cardiac injury directly at the patient site, reducing delays associated with centralized laboratory testing. This approach is particularly valuable in managing acute coronary syndrome and cardiac injury monitoring, where time-sensitive decision-making is essential. Increased investment in decentralized diagnostic infrastructure is further supporting adoption across hospitals and ambulatory care facilities.
Market Segmentation
- Based on the type, the market is segmented into creatine kinase, troponins, myoglobin, ischemia modified albumin, natriuretic peptides (BNP and NT-proBNP), and others.
- Based on the application, the market is segmented into acute coronary syndrome, congestive heart failure, cardiac injury monitoring, myocardial infarction, and others.
- Based on the testing, the market is segmented into laboratory testing, and point-of-care testing.
Troponins Segment Driving Diagnostic Demand Within the Type Category
The troponins segment represents a leading contributor to growth within the global cardiac marker market due to its central role in diagnosing acute coronary syndrome. Troponin I and T are widely adopted as first-line biomarkers owing to their high cardiac specificity and clinical reliability. Increasing use of troponin testing in emergency departments and routine hospital workflows continues to expand test volumes globally. Ongoing improvements in assay sensitivity are reinforcing clinical preference for troponins over older markers such as CK-MB.
Point of Care Testing Supporting Rapid Decision-Making in the Testing Segment
Point-of-care testing is a key growth sub-segment within the testing category of the global cardiac marker market, supported by demand for rapid diagnostic turnaround in acute care settings. These tests enable immediate assessment of cardiac markers at the patient site, reducing dependency on centralized laboratories. Adoption is particularly strong in emergency rooms, ambulances, and smaller healthcare facilities where time-critical decisions are required. The increasing availability of compact and reliable point-of-care cardiac marker devices is improving test accessibility across regions.
Regional Outlook
The global cardiac marker market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America as the Leading Region in the Global Cardiac Marker Market
North America holds a leading position in the global cardiac marker market due to its well-established healthcare infrastructure and high adoption of advanced diagnostic technologies. The region demonstrates strong demand for laboratory-based and point-of-care cardiac marker testing, supported by standardized clinical guidelines for acute coronary syndrome management. A high prevalence of cardiovascular conditions continues to drive consistent testing volumes across hospitals and diagnostic laboratories. Ongoing product advancements in high-sensitivity troponin assays further strengthen market maturity in the US and Canada.
Asia-Pacific as the Fastest Growing Region in the Global Cardiac Marker Market
Asia-Pacific represents the fastest-growing region in the global cardiac marker market, driven by rising cardiovascular disease burden and expanding access to diagnostic services. Increasing investments in healthcare infrastructure and diagnostic laboratories are accelerating the adoption of cardiac marker testing across both urban and secondary care settings. Growth in point-of-care testing is particularly notable, supporting faster diagnosis in emergency and resource-limited environments. Greater awareness of early cardiac risk assessment among clinicians is contributing to higher test utilization. Rapid market expansion across countries such as China, India, and Southeast Asia positions the Asia-Pacific as a key growth engine for the market.
Market Players Outlook
The major companies operating in the global cardiac marker market include Abbott Laboratories, bioMérieux SA, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers and acquisitions strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In October 2024, Siemens Healthineers received FDA clearance for its Atellica IM high-sensitivity troponin I (TnIH) test, which helps identify patients at risk of death or major cardiac events up to one year after presenting with acute coronary syndrome symptoms.
- In July 2024, Roche completed its acquisition of LumiraDx’s Point of Care technology after receiving all regulatory approvals. The acquisition adds LumiraDx’s multi-assay platform, which integrates various immunoassay and clinical chemistry tests on one device, to Roche’s diagnostics portfolio.
- In June 2024, Siemens Healthineers introduced the NT-proBNPII (PBNPII) assay on its Atellica Solution to aid heart failure diagnosis. NT-proBNP and BNP are cardiac stress markers released due to increased ventricular pressure. The PBNPII assay delivers results in 10 minutes, enhancing timely care. Both assays run on Atellica® IM or CI analyzers, offering flexibility.
- In October 2023, Mindray launched new high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers to enhance its cardiac diagnostic portfolio. These biomarkers are crucial for early detection and management of cardiovascular diseases (CVDs), the leading global cause of death. Developed in partnership with HyTest, a leader in cardiac biomarker expertise acquired by Mindray in 2021, the assays have been clinically validated by institutions in China and the US.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global cardiac marker market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Cardiac Marker Market Sales Analysis – Type | Application | Testing ($ Million)
- Cardiac Marker Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Cardiac Marker Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Cardiac Marker Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Cardiac Marker Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Cardiac Marker Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Cardiac Marker Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Cardiac Marker Market Revenue and Share by Manufacturers
- Cardiac Marker Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Abbott Laboratories
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- bioMérieux SA
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Hoffmann-La Roche Ltd
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Siemens Healthineers AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Thermo Fisher Scientific Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Abbott Laboratories
- Key Company Analysis
- Global Cardiac Marker Market Sales Analysis by Type ($ Million)
- Creatine Kinase (CK-MB)
- Troponins (T,I)
- Myoglobin
- Natriuretic Peptides (BNP and NT-proBNP)
- Ischemia Modified Albumin (IMA)
- Others
- Global Cardiac Marker Market Sales Analysis by Application ($ Million)
- Acute Coronary Syndrome
- Congestive Heart Failure
- Cardiac Injury Monitoring
- Myocardial Infarction
- Others
- Global Cardiac Marker Market Sales Analysis by Testing ($ Million)
- Laboratory testing
- Point of Care Testing
- Regional Analysis
- North American Cardiac Marker Market Sales Analysis – Type | Application | Testing | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Cardiac Marker Market Sales Analysis – Type | Application | Testing | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Cardiac Marker Market Sales Analysis – Type | Application | Testing | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Cardiac Marker Market Sales Analysis – Type | Application | Testing | Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Abbott Laboratories
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AdvaCare Pharma
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Antu Biotechnology Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bio-Rad Laboratories, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- bioMérieux SA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Danaher Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- DiaSorin S.p.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- DiaSys Diagnostic Systems GmbH
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hoffmann-La Roche Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Fujirebio Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Guangzhou Wondfo Biotech Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Lifotronic Technology Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ortho Clinical Diagnostics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Randox Laboratories Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Siemens Healthineers AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Snibe Diagnostics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sysmex Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Thermo Fisher Scientific Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Tosoh Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Abbott Laboratories
1. Global Cardiac Marker Market Research and Analysis by Type, 2025–2035 ($ Million)
2. Global Creatine Kinase (CK-MB) Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Troponins (T, I) Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Myoglobin Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Natriuretic Peptides (BNP and NT-proBNP) Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Ischemia Modified Albumin (IMA) Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Other Cardiac Marker Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Cardiac Marker Market Research and Analysis by Application, 2025–2035 ($ Million)
9. Global Cardiac Marker For Acute Coronary Syndrome Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Cardiac Marker For Congestive Heart Failure Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Cardiac Marker For Cardiac Injury Monitoring Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Cardiac Marker For Myocardial Infarction Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Cardiac Marker For Other Application Market Research and Analysis by Region, 2025–2035 ($ Million)
14. Global Cardiac Marker Market Research and Analysis by Testing, 2025–2035 ($ Million)
15. Global Cardiac Markers by Laboratory Testing Market Research and Analysis by Region, 2025–2035 ($ Million)
16. Global Cardiac Markers by Point of Care Testing Market Research and Analysis by Region, 2025–2035 ($ Million)
17. Global Cardiac Marker Market Research and Analysis by Region, 2025–2035 ($ Million)
18. North American Cardiac Marker Market Research and Analysis by Country, 2025–2035 ($ Million)
19. North American Cardiac Marker Market Research and Analysis by Type, 2025–2035 ($ Million)
20. North American Cardiac Marker Market Research and Analysis by Application, 2025–2035 ($ Million)
21. North American Cardiac Marker Market Research and Analysis by Testing, 2025–2035 ($ Million)
22. European Cardiac Marker Market Research and Analysis by Country, 2025–2035 ($ Million)
23. European Cardiac Marker Market Research and Analysis by Type, 2025–2035 ($ Million)
24. European Cardiac Marker Market Research and Analysis by Application, 2025–2035 ($ Million)
25. European Cardiac Marker Market Research and Analysis by Testing, 2025–2035 ($ Million)
26. Asia-Pacific Cardiac Marker Market Research and Analysis by Country, 2025–2035 ($ Million)
27. Asia-Pacific Cardiac Marker Market Research and Analysis by Type, 2025–2035 ($ Million)
28. Asia-Pacific Cardiac Marker Market Research and Analysis by Application, 2025–2035 ($ Million)
29. Asia-Pacific Cardiac Marker Market Research and Analysis by Testing, 2025–2035 ($ Million)
30. Rest of the World Cardiac Marker Market Research and Analysis by Region, 2025–2035 ($ Million)
31. Rest of the World Cardiac Marker Market Research and Analysis by Type, 2025–2035 ($ Million)
32. Rest of the World Cardiac Marker Market Research and Analysis by Application, 2025–2035 ($ Million)
33. Rest of the World Cardiac Marker Market Research and Analysis by Testing, 2025–2035 ($ Million)
1. Global Cardiac Marker Market Share by Type, 2025 vs 2035 (%)
2. Global Creatine Kinase (CK-MB) Market Share by Region, 2025 vs 2035 (%)
3. Global Troponins (T,I) Market Share by Region, 2025 vs 2035 (%)
4. Global Myoglobin Market Share by Region, 2025 vs 2035 (%)
5. Global Natriuretic Peptides (BNP and NT-proBNP) Market Share by Region, 2025 vs 2035 (%)
6. Global Ischemia Modified Albumin (IMA) Projection Market Share by Region, 2025 vs 2035 (%)
7. Global Other Cardiac Marker Market Share by Region, 2025 vs 2035 (%)
8. Global Cardiac Marker Market Share by Application, 2025 vs 2035 (%)
9. Global Cardiac Marker For Acute Coronary Syndrome Market Share by Region, 2025 vs 2035 (%)
10. Global Cardiac Marker For Congestive Heart Failure Market Share by Region, 2025 vs 2035 (%)
11. Global Cardiac Marker For Cardiac Injury Monitoring Market Share by Region, 2025 vs 2035 (%)
12. Global Cardiac Marker For Myocardial Infarction Market Share by Region, 2025 vs 2035 (%)
13. Global Cardiac Marker For Other Application Market Share by Region, 2025 vs 2035 (%)
14. Global Cardiac Marker Market Share by Testing, 2025 vs 2035 (%)
15. Global Cardiac Marker by Laboratory Testing Market Share by Region, 2025 vs 2035 (%)
16. Global Cardiac Marker by Point of Care Testing Market Share by Region, 2025 vs 2035 (%)
17. Global Cardiac Marker Market Research and Analysis by Region, 2025–2035 ($ Million)
18. US Cardiac Marker Market Size, 2025–2035 ($ Million)
19. Canada Cardiac Marker Market Size, 2025–2035 ($ Million)
20. UK Cardiac Marker Market Size, 2025–2035 ($ Million)
21. France Cardiac Marker Market Size, 2025–2035 ($ Million)
22. Germany Cardiac Marker Market Size, 2025–2035 ($ Million)
23. Italy Cardiac Marker Market Size, 2025–2035 ($ Million)
24. Spain Cardiac Marker Market Size, 2025–2035 ($ Million)
25. Russia Cardiac Marker Market Size, 2025–2035 ($ Million)
26. Rest of Europe Cardiac Marker Market Size, 2025–2035 ($ Million)
27. India Cardiac Marker Market Size, 2025–2035 ($ Million)
28. China Cardiac Marker Market Size, 2025–2035 ($ Million)
29. Japan Cardiac Marker Market Size, 2025–2035 ($ Million)
30. South Korea Cardiac Marker Market Size, 2025–2035 ($ Million)
31. Australia and New Zealand Cardiac Marker Market Size, 2025–2035 ($ Million)
32. ASEAN Economies Cardiac Marker Market Size, 2025–2035 ($ Million)
33. Rest of Asia-Pacific Cardiac Marker Market Size, 2025–2035 ($ Million)
34. Latin America Cardiac Marker Market Size, 2025–2035 ($ Million)
35. Middle East and Africa Cardiac Marker Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Cardiac Marker Market in 2025 is estimated to be around $4.8 billion.
North America holds the largest share in the Cardiac Marker Market.
Leading players in the Cardiac Marker Market include Abbott Laboratories, bioMérieux SA, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Thermo Fisher Scientific Inc., among others.
The Cardiac Marker Market is expected to grow at a CAGR of 14.3% from 2026 to 2035.
The Cardiac Marker Market growth is driven by rising prevalence of cardiovascular diseases and increasing demand for rapid and accurate diagnostic testing.
